HCV Therapy Demonstrates 98% Sustained Virologic Response at 12 Weeks Post-Treatment

HCV Therapy Demonstrates 98% Sustained Virologic Response at 12 Weeks Post-Treatment

Atea Pharmaceutical’s investigational combination treatment of bemnifosbuvir and ruzasvir showed these results after an 8-week treatment regimen.

Bemnifosbuvir, Ruzasvir Regimen Shows Strong Efficacy as HCV Treatment

A phase 2 study found 95% of patients achieved a sustained virologic response at 12 weeks regardless of treatment adherence.